Shareholders Approve Esperion Therapeutics Acquisition by Essence Parent
ESPR has more than doubled off its 52-week low of $1.1 on light trading volume (0.3× avg).
Summary
Esperion Therapeutics' shareholders have officially approved the company's acquisition by Essence Parent Inc., moving the merger closer to completion.
Key Events · M&A and Partnerships · ESPR
-
Shareholder Approval of Merger Agreement
Esperion Therapeutics' stockholders voted to adopt the Agreement and Plan of Merger with Essence Parent Inc. on July 8, 2026. This was a critical condition for the acquisition to proceed.
-
Advisory Compensation Proposal Approved
Stockholders also approved, by an advisory (non-binding) vote, the compensation for named executive officers in connection with the merger.
-
Quorum Achieved
A total of 158,573,615 shares, representing 61.53% of outstanding common stock, were represented at the special meeting, constituting a quorum.
Analysis · ESPR · Life Sciences
This 8-K confirms that Esperion Therapeutics' stockholders have approved the merger agreement with Essence Parent Inc. This vote was a critical condition for the acquisition to proceed, following earlier announcements of the definitive agreement and antitrust clearances. The approval removes a significant hurdle, paving the way for the transaction's completion.
How filings like this one have moved
In the 30 days to Aug 23, 2026, 43.6% of the 999 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.10%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ESPR was trading at $3.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $816.9M. The 52-week trading range was $1.10 to $4.18. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.